 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on May 28, 2008 |
| Title |
Gene Expression Patterns Involved in the Malignant Transformation and Progression of Metastatic Melanoma |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Metastatic melanoma is a deadly disease while non-metastatic melanoma and other cutaneous tumor types are usually cured with surgical removal of the primary tumors. This study evaluated gene expresion to determine if gene expression differences existed which would allow one to identify the metastatic tumors based on the expression of specific genes.
Keywords: multiple tissue comparison
|
| |
|
| Overall design |
Tumor samples were collected from patients with various cutaneous tumors, flash frozen, and then processed for gene exprression analysis using microarrays. The pool of tissues includes enough metastatic samples and non-metastatic samples to identify a gene expression signature associated with the outgrowth of the metastatic tumor.
|
| |
|
| Contributor(s) |
Riker AI, Enkemann SA, Liu S, Ren S, Briggs J, Xi Y, Howell P, Eschrich S, Daud A, Messina J, D'Alessio M, Sondak VK, Jove R, Beuttner R, Samant RS, Shevde LA, Ju J, Fodstad O, Matta J |
| Citation(s) |
18442402 |
| Submission date |
Apr 19, 2007 |
| Last update date |
Mar 25, 2019 |
| Contact name |
Sean Yoder |
| E-mail(s) |
sean.yoder@moffitt.org
|
| Phone |
813-745-1917
|
| Organization name |
Moffitt Cancer Center & Research Institute
|
| Department |
Molecular Genomics Core Facility
|
| Lab |
SRB-2
|
| Street address |
12902 Magnolia Dr.
|
| City |
Tampa |
| State/province |
FL |
| ZIP/Postal code |
33612 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL570 |
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array |
|
| Samples (87)
|
| GSM183218 |
Group 1, Basal cell carcinoma, 7797_8 |
| GSM183219 |
Group 1, Basal cell carcinoma, 7800_11 |
| GSM183220 |
Group 1, Basal cell carcinoma, 7843_15 |
| GSM183221 |
Group 1, Basal cell carcinoma, 7845_17 |
| GSM183222 |
Group 1, Melanoma in situ, 7795_6 |
| GSM183223 |
Group 1, Melanoma in situ, 7846_18 |
| GSM183224 |
Group 1, Primary Melanoma, 7790_1 |
| GSM183225 |
Group 1, Primary Melanoma, 7840_12 |
| GSM183226 |
Group 1, Metastatic Melanoma, 6611 A1 |
| GSM183227 |
Group 1, Metastatic Melanoma, 6611 A2 |
| GSM183228 |
Group 1, Metastatic Melanoma, 6611 A3 |
| GSM183229 |
Group 1, Metastatic Melanoma, 6611 B |
| GSM183230 |
Group 1, Metastatic Melanoma, 6685 A |
| GSM183231 |
Group 1, Metastatic Melanoma, 6685 B |
| GSM183232 |
Group 1, Metastatic Melanoma, 7838 B |
| GSM183233 |
Group 1, Metastatic Melanoma, 7838 D |
| GSM183234 |
Group 1, Normal Skin, 6611 A5 |
| GSM183235 |
Group 1, Primary Melanoma, 7838 A |
| GSM183236 |
Group 1, Squamous cell carcinoma, 7794_5 |
| GSM183237 |
Group 1, Squamous cell carcinoma, 7796_7 |
| GSM183238 |
Group 1, Squamous cell carcinoma, 7798_9 |
| GSM183239 |
Group 1, Squamous cell carcinoma, 7842_14 |
| GSM183240 |
Group 1, Squamous cell carcinoma, 7844_16 |
| GSM183241 |
Group 2, Basal cell carcinoma, 8285-21 |
| GSM183242 |
Group 2, Basal cell carcinoma, 8286-22 |
| GSM183243 |
Group 2, Basal cell carcinoma, 8288-24 |
| GSM183244 |
Group 2, Basal cell carcinoma, 8290-26 |
| GSM183245 |
Group 2, Basal cell carcinoma, 8291-27 |
| GSM183246 |
Group 2, Basal cell carcinoma, 8292-28 |
| GSM183247 |
Group 2, Basal cell carcinoma, 8293-29 |
| GSM183248 |
Group 2, Basal cell carcinoma, 8294-30 |
| GSM183249 |
Group 2, Basal cell carcinoma, 8295-31 |
| GSM183250 |
Group 2, Basal cell carcinoma, 8296-32 |
| GSM183251 |
Group 2, Basal cell carcinoma, 8297-33 |
| GSM183252 |
Group 2, Metastatic Melanoma, 6933A-10 |
| GSM183253 |
Group 2, Metastatic Melanoma, 7051B-27 |
| GSM183254 |
Group 2, Metastatic Melanoma, 7129A-11 |
| GSM183255 |
Group 2, Metastatic Melanoma, 7322B-24 |
| GSM183256 |
Group 2, Metastatic Melanoma, 7510A-30 |
| GSM183257 |
Group 2, Metastatic Melanoma, 7838D-2 |
| GSM183258 |
Group 2, Primary Melanoma, 7838A-15 |
| GSM183259 |
Group 2, Primary Melanoma, 6705A-12 |
| GSM183260 |
Group 2, Primary Melanoma, 6924A-18 |
| GSM183261 |
Group 2, Primary Melanoma, 7062A-3 |
| GSM183262 |
Group 2, Primary Melanoma, 7156B-29 |
| GSM183263 |
Group 2, Primary Melanoma, 7288B-21 |
| GSM183264 |
Group 2, Primary Melanoma, 7327A-7 |
| GSM183265 |
Group 2, Primary Melanoma, 7682B-31 |
| GSM183266 |
Group 2, Primary Melanoma, 8033G-17 |
| GSM183267 |
Group 2, Squamous cell carcinoma, 8284-20 |
| GSM183268 |
Group 2, Squamous cell carcinoma, 8287-23 |
| GSM183269 |
Group 2, Squamous cell carcinoma, 8289-25 |
| GSM183270 |
Group 2, Squamous cell carcinoma, 8298-34 |
| GSM183271 |
Group 2, Squamous cell carcinoma, 8299-35 |
| GSM183272 |
Group 2, Squamous cell carcinoma, 8300-36 |
| GSM183273 |
Group 3, Metastatic Melanoma, T6425A |
| GSM183274 |
Group 3, Metastatic Melanoma, T6435A |
| GSM183275 |
Group 3, Metastatic Melanoma, T6519A1 |
| GSM183276 |
Group 3, Metastatic Melanoma, T6807A |
| GSM183277 |
Group 3, Metastatic Melanoma, T6829A |
| GSM183278 |
Group 3, Metastatic Melanoma, T6851A |
| GSM183279 |
Group 3, Metastatic Melanoma, T6950B |
| GSM183280 |
Group 3, Metastatic Melanoma, T6952B |
| GSM183281 |
Group 3, Metastatic Melanoma, T7126D |
| GSM183282 |
Group 3, Metastatic Melanoma, T7133B |
| GSM183283 |
Group 3, Metastatic Melanoma, T7223A |
| GSM183284 |
Group 3, Metastatic Melanoma, T7336A |
| GSM183285 |
Group 3, Metastatic Melanoma, T7533A |
| GSM183286 |
Group 3, Metastatic Melanoma, T7711A |
| GSM183287 |
Group 3, Metastatic Melanoma, T7746D |
| GSM183288 |
Group 3, Metastatic Melanoma, T7784A |
| GSM183289 |
Group 3, Metastatic Melanoma, T7851A |
| GSM183290 |
Group 3, Metastatic Melanoma, T7859A |
| GSM183291 |
Group 3, Metastatic Melanoma, T8032D |
| GSM183292 |
Group 3, Metastatic Melanoma, T8122A |
| GSM183293 |
Group 3, Metastatic Melanoma, T8202A |
| GSM183294 |
Group 3, Metastatic Melanoma, T8244A |
| GSM183295 |
Group 3, Metastatic Melanoma, T8248C |
| GSM183296 |
Group 3, Metastatic Melanoma, T8268A |
| GSM183297 |
Group 3, Metastatic Melanoma, T8486D |
| GSM183298 |
Group 3, Metastatic Melanoma, T8647A |
| GSM183299 |
Group 3, normal human epidermal melanocytes, NHEM |
| GSM183300 |
Group 3, Normal Skin, N7288C |
| GSM183301 |
Group 3, Normal Skin, N7598J |
| GSM183302 |
Group 3, Normal Skin, N7600G |
| GSM183303 |
Group 3, Primary Melanoma, T6516I |
| GSM183304 |
Group 3, Primary Melanoma, T6950A |
|
| Relations |
| BioProject |
PRJNA100369 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE7553_RAW.tar |
479.3 Mb |
(http)(custom) |
TAR (of CEL, CHP) |
| Processed data provided as supplementary file |
|
|
|
|
 |
Less...
More...